As Canadian officials plan for a worst-case scenario while expecting a new wave of coronavirus to drive up cases by more than 1,000 per day over the next week, the government upped its order with Moderna to secure an additional 14 million doses of its COVID-19 vaccine – totaling 56 million.
Within Canada’s previous agreement, it held an option to increase its purchase depending on how Moderna’s trial phases panned out.
Moderna’s vaccine candidate – mRNA-1273 – is nearing the finishing line in its push to enroll 30,000 individuals during a late-stage trial of a completely unique coronavirus vaccine. As of last week, Moderna had enrolled 25,296 participants.
Moderna, which made its protocols public on Thursday, said its first improvised analysis of 53 infections is probably going to come in November.
“We appreciate the arrogance in Moderna’s mRNA platform and therefore the progress we are making with mRNA-1273, as demonstrated by the increased order from the Canadian government today,” said Moderna CEO Stephane Bancel. “This support, alongside our stakeholders, drives us forward as we scale-up our global manufacturing and distribution network.”
If Moderna’s COVID vaccine proves to be a minimum of 70% effective, the corporate plans to seek emergency authorization for its use in high-risk groups, Bancel told Reuters.
An independent safety board will take a primary check out Moderna’s data as soon as a complete of 53 people in the trial become infected with COVID. Moderna is projecting the improvised analysis will occur in November, but it could come as early as October.
If most of the people that got sick got the placebo shot, that might indicate the vaccine was protecting those inoculated and will be enough evidence to get US regulatory approval for Emergency Use Authorization (EUA).
Moderna says that they remain on track to deliver the doses to Canadians beginning in 2021, sourced via Moderna’s European production capacity working with its new strategic partner in Lonza of Switzerland as well as ROVI of Spain.